Date of event
-
Continuing Education Credits
CME
ABIM MOC
Add to Calendar 2022-07-22 08:00:00 2022-07-23 14:00:00 2022 Emerging Topic Conference - Reproductive Health in Liver Disease     Philadelphia, PA United States AASLD alonzo.tolver@boldrstrategy.com America/New_York public

Course Description/Need Statement

The conference, Reproductive Health in Liver Disease, will apply knowledge from the growing contemporary literature to dispel pre-existing myths surrounding reproductive health in chronic liver disease. Updated data will be presented in the context of sexual dysfunction and reproductive counseling in chronic liver disease, as well as risk stratification of pregnancy and management recommendations for patients with chronic liver disease from pre-conception through delivery. 

Program Chairs

  • Maria D. Hernandez, MD
  • Monika Sarkar, MD
  • Kidist K. Yimam, MD

REGISTRATION

Conference registration is now open. Register Now

CONFERENCE FORMAT

The online live-streaming conference will have pre-recorded presentations for viewing along with live elements such as panel discussions, oral abstract presentations, and the opportunity to get your faculty questions answered in real time with both Chat and Q&A features available throughout the event.

ABSTRACTS

The conference abstract submitter is open and will close at 11:59 pm ET on July 6. Abstracts submitted will be reviewed by the Program Chairs for potential virtual poster and/or oral abstract presentation. 

Submit an Abstract Now

CONTINUING EDUCATION

CME Hours: 7.25 AMA PRA Category 1 Credits™
ABIM MOC Points: 7.25 ABIM MOC Points

Registration Pricing Early Bird: On or Before JULY 8

Member - $210
Non-Member - $290
Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
Trainee & Associate Member -  $150
Trainee & Associate Non-Member -  $230
Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
Student Member - $75
Student Non-Member - $115
Industry - $700
Any Industry (pharma/device/etc.) employee with or without medical training.
Patient Advocates: $25
Patients & Caregivers: $25
Registration scholarships are available by request for the Patient Advocates and Patients Caregivers categories. Please contact Michael Providence at mprovidence@aasld.org for further details.

Registration Pricing: On or After JULY 9

Member - $260
Non-Member - $390
Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
Trainee & Associate Member -  $200
Trainee & Associate Non-Member -  $350
Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
Student Member - $115
Student Non-Member - $115
Industry - $800
Any Industry (pharma/device/etc.) employee with or without medical training.
Patient Advocates: $25
Patients & Caregivers: $25
Registration scholarships are available by request for the Patient Advocates and Patients Caregivers categories. Please contact Michael Providence at mprovidence@aasld.org for further details.

Registration Cancellation Policy

Requests for cancellations must be submitted in writing to meetings@aasld.org.

 

Cancellations received by Friday, July 8, 2022 will be refunded in full.

Cancellations received between July 9 –  July 21, 2022 will be subject to a $50.00 cancellation fee.

Cancellations received on or after July 22, 2022 are not eligible for a refund.

Credits Offered

Continuing Medical Education (CME): 7.25 AMA PRA Category 1 Credits

ABIM Maintenance of Certification (MOC): 7.25 ABIM MOC Points

Accreditation and Designation Statements

Continuing Medical Education (CME) 
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.  Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.  It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Claiming CME Credits and ABIM MOC Points

CME Credits

Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Monday, August 15, 2022. A link to the CME evaluation will be emailed to attendees after the meeting.

MOC Points 

Physicians seeking ABIM MOC points must complete the CME and MOC evaluation by Monday, August 15, 2022.  Requests for MOC after this date will not be honored.  The MOC evaluation is included in the CME evaluation.

MOC Points will be reported to the ABIM by the end of August 2022 for attendees who successfully complete the MOC evaluation.

COURSE DESCRIPTION/Needs Statement

The conference, Reproductive Health in Liver Disease, will apply knowledge from the growing contemporary literature to dispel pre-existing myths surrounding reproductive health in chronic liver disease. Updated data will be presented in the context of sexual dysfunction and reproductive counseling in chronic liver disease, as well as risk stratification of pregnancy and management recommendations for patients with chronic liver disease from pre-conception through delivery. 

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Manage major categories of chronic liver disease in pregnancies, risk stratify cirrhotic patients seeking pregnancy and manage portal hypertensive complications in pregnancy
  • Provide reproductive counseling in pre- and post-LT male and female patients and discuss safety of contraceptives in the context of various liver conditions
  • Understand safety of modalities of imaging in pregnancy and lactation and determine when a biopsy would be indicated.

Target Audience

  • Hepatologists
  • Gastroenterologists
  • Nurse Practitioners
  • Pharmacists
  • Physician Assistants
  • Transplant Coordinators
  • Surgeons
  • Fellows/Trainees
  • Internal and Family Medicine Providers
  • Obstetricians and Gynecologists

Friday, July 22, 2022

Session I: Sexual Function, Sexual Activity and Fertility Considerations in Male and Female Patients with Liver Disease

ModeratorS: Erica Villa, MD and Monika Sarkar, MD, MAS

  • 10 am – 10:15 am
    Sexual Health in Adolescents: Introducing Transitions in Care and Patient Scaffold
    Jean P. Molleston, MD
  • 10:15 am – 10:30 am
    Sexual Dysfunction in Men and Women with Liver Disease: Where We Fall Short 
    Patrizia Burra, MD, PhD, FAASLD
  • 10:30 am – 10:45 am
    Updates in Contraception Management: Where the AASLD and CDC Diverge 
    Sara Whetstone, MD
  • 10:45 am – 11 am
    Fertility Treatment in Liver Disease
    Vandana Khungar, MD, MSc
  • 11 am – 11:15 am
    Panel Discussion
  • 11:15 am – 11:30 am    
    Break

Friday, July 22, 2022

Session II: Reproductive Health Considerations with Chronic Liver Disease

ModeratorS: Maria D. Hernandez, MD and Vandana Khungar, MD, MSc

  • 11:30 am – 11:45 am
    Understanding Hormones and Liver Disease: Menopause, Andropause, and Transgender Health 
    Carla W. Brady, MD, MHS, FAASLD
  • 11:45 am – Noon
    Hepatitis C in Pregnancy- Time for Third Trimester Treatment?  
    Norah Terrault, MD, MPH, FAASLD
  • Noon – 12:15 pm
    Intrahepatic Cholestasis: Rethinking the Role of Ursodiol
    Cynthia Levy, MD, FAASLD
  • 12:15 pm – 12:30 pm
    Reproductive Health and NAFLD: Enter PCOS and Pregnancy
    Monika Sarkar, MD, MAS
  • 12:30 pm – 12:50 pm
    Panel Discussion
  • 12:50 pm – 1:20 pm
    Lunch

Friday, July 22, 2022

Session III: Diagnostic Testing and Pharmacology Safety in Pregnancy

ModeratorS: Carla W. Brady, MD, MHS, FAASLD and Norah Terrault, MD, MPH, FAASLD

  • 1:20 pm – 1:35 pm
    Approach to Liver Tests in Pregnancy- What’s Normal, What’s Not
    Jaquelyn F. Fleckenstein, MD, FACP, FAASLD
  • 1:35 pm – 1:50 pm
    Imaging (Including Elastography) and Biopsy in Pregnancy and Lactation  
    Erica Villa, MD
  • 1:50 pm – 2:05 pm
    Safety of Common Liver-Related Medications in Pregnancy and Lactation: The Move from FDA Categories to Individualized Approach
    Tatyana Kushner, MD, MSCE
  • 2:05 pm – 2:30 pm
    Panel Discussion

SATURDAY, July 23, 2022

Session IV: Cirrhosis and Liver Lesions in Pregnancy- Pre-conception Through Delivery

ModeratorS: Kimberly A. Forde, MD, PhD, MHS and Monika Sarkar, MD, MAS

  • 10 am – 10:15 am
    Evolving Epidemiology and Prognostic Scoring for Cirrhosis in Pregnancy 
    Jennifer A. Flemming, MD
  • 10:15 am – 10:30 am
    Variceal Screening and Management- The Changing Landscape of Risk 
    Maria D. Hernandez, MD
  • 10:30 am – 10:45 am
    Hepatic Adenomas and Pregnancy  
    Jennifer E. Guy, MD, MAS
  • 10:45 am – 11:05 am
    Panel Discussion / Q&A
  • 11:05 am – 11:15 am
    Break

SATURDAY, July 23, 2022

Session V: Reproductive Potpourri

ModeratorS: MONIKA SARKAR, MD, MAS and Tatyana Kushner, MD, MSCE

  • 11:15 am – 11:30 am
    Time to Step-Up: The Role of Transplant Providers in Pre-Conception Counseling
    Monika Sarkar, MD, MAS
  • 11:30 am – 11:45 am
    Transplant Med Management in Men and Women Starting Families: Dispelling Myths with Registry Data
    Lisa Coscia, RN, BSN, CCTC
  • 11:45 am – Noon    
    Conducting Liver Research in Pregnancy: Advice from the Obstetric Lens
    Yalda Afshar, MD, PhD
  • Noon – 12:15 pm
    Case Presentations: Management Dilemmas in Pregnancy
    Kidist Yimam, MD
    Panelists: Michael A. Heneghan, MD, MMedSc, FRCPI
    Michele M. Tana, MD
  • 12:15 pm – 12:45 pm
    Lunch

SATURDAY, July 23, 2022

Session VI: Oral Abstract Presentations-Advancing Gaps in Liver Disease Management in Pregnancy

ModeratorS: Kimberly A. Forde, MD, PhD, MHS and Monika Sarkar, MD. MAS

  • 12:45 pm – 12:55 pm
    Oral Abstract Presentation #1
  • 12:55 pm – 1:05 pm
    Oral Abstract Presentation #2
  • 1:05 pm – 1:15 pm
    Oral Abstract Presentation #3
  • 1:15 pm – 1:25 pm
    Oral Abstract Presentation #4
  • 1:25 pm – 1:35 pm
    Panel Discussion/Q&A
  • 1:35 pm – 1:45 pm
    Wrap-Up and Future Directions
    Maria D. Hernandez, MD 
  • 1:45 pm    
    Adjourn

Submission Deadlines

Abstract submissions are now being accepted. Submit your work for consideration.
Opens: Wednesday, June 8, 2022
Closes: Wednesday, July 6, 2022

Overview

Abstracts submitted will be reviewed by the Program Chairs for potential virtual poster and/or oral abstract presentation.  If selected, the presenting author will be required to accept the invitation to present, register for the conference, and provide current financial disclosure information.

Abstract notification will be sent to presenting authors by mid-July.

Title

The title should be brief, but long enough to identify the nature of the study. Omit author names and medical degrees and institutional appointments in the title. The maximum for the title character count is 300.

Abstract Body

The body of the abstract needs to include:

  • A background
  • Description of methods
  • Summary of results obtained
  • Statement of conclusion reached

There is a set 3,000 maximum character count for the abstract body.

Attachments

You may include any supporting images/tables. Images and tables are not a part of the overall character count.

Accepted files: pdf, jpg, jpeg, png, csv, doc(x), and ppt under 5MB

Author Types

Only one presenting and corresponding author may be selected – see author definitions below

  • Co-Author – One of several authors who provided a significant contribution to the abstract.
  • Corresponding Author – This author will receive all notifications regarding the abstract, and will be expected to make any changes requested by the abstract reviewers.
  • Presenting Author – The author who will be presenting the poster at the meeting.

The maximum number of authors on an abstract is 30.

Questions

For questions about the abstract submission process, please send an email to abstracts@aasld.org .

Ethics Policy

The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals.

  • For reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials.
  • HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.
  • In studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

Disclosure Policy

All faculty members (including Program Planners, Program Chairs, Moderators, Panelists, and Presenters) are expected to fully disclose all financial relationships with a commercial interest. By accepting our invitation, you agreed to comply with AASLD's Disclosure Policy and the ACCME Standards for Commercial Support in the planning, development, and presentation of educational activities.
 

Presentations may be recorded for printed and electronic distribution by AASLD. This includes posting on the eLearning portal LiverLearning®, and any AASLD affiliated websites and printed communications. If a course is selected for recording, presenters will have the ability to accept or decline this policy prior to the meeting.
 

OFF-LABEL, INVESTIGATIONAL USE

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is included in the content of the educational activity, you are required to verbally disclose that the product is not labeled for the use under discussion or that the product is still investigational, in accordance with the ACCME standards and the Food and Drug Administration requirements.